ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.
On July 3, 2025, Congress passed the final version of its 2025 budget reconciliation legislation. The American Cancer Society Cancer Action Network strongly opposed the health changes included in the bill, which the Congressional Budget Office estimates would reduce the number of people with health insurance by 10 million people by 2034 through major cuts to Medicaid and changes to Marketplace and other coverage.
The One Big Beautiful Bill Act (Pub. Law No. 119-21) prohibits states from auto-enrolling people into Marketplace plans (regardless of whether the Marketplace is state-based or federally run).
Nearly all (94%) cancer patients and survivors agree that it is important for patients and their providers to have the ability to choose the type of treatment and delivery that best suits their needs. Patients who have taken oral anti-cancer drugs rate their experience significantly better compared to experiences with IV infusions on several metrics including coping with side effects, time spent in provider visits, and quality of life.
Our latest Survivor Views survey finds that across party lines cancer patients and survivors oppose reducing funding for Medicaid (73%), and fewer than one-in-five support adding a work requirement for Medicaid (19%). The survey also finds overwhelming support for protecting coverage for those with preexisting conditions (81%), and explores questions related to allowing non-ACA plans in the marketplace, which a majority (65%) feel would be confusing.
Our latest survey finds that 86% of those receiving enhanced premium tax credits would have difficulty getting care if the credits expire at the end of 2025, and very few (25%) are aware of the enhanced credits expiring.
A majority of cancer patients and survivors struggle to afford cancer care and over 80% have had to make financial sacrifices to cover their health care expenses. This survey also reveals ways that affordability concerns can negatively impact care and treatment, and explores issues related to prescription drug coverage and pain management options.
Many cancer patients take multiple drugs as part of their treatment – often for many months or years. While drugs are not the only costly part of cancer treatment, finding ways to reduce these costs for patients and payers will significantly reduce the overall cost burden of cancer.
This Survivor Views survey examined access to and affordability of cancer care. Survivors report insurance-related barriers to obtaining prescriptions, and lower-income respondents in particular have difficulty affording them. 24% of respondents have received a surprise medical bill, 60% of which were more than $500.
Biological drugs, commonly referred to as biologics, are a class of drugs that are produced using a living system, such as a microorganism, plant cell, or animal cell. Like all drugs, biologics are regulated by the United States Food and Drug Administration (FDA).
For an individual with specific health care needs – like cancer patients and survivors – the drugs covered by a health plan and corresponding cost sharing for each drug is important information when choosing health insurance. However, to make an informed choice, formulary information must be disclosed to the individual.
ACS CAN joined with 50 other organizations to applaud Representatives Jodey Arrington (R-TX) and Terri Sewell (D-AL) for sponsoring and prioritizing the passage of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 842).
Earlier screening for cancer is important because when detected at later stages, treatments are more limited, and outcomes are generally poorer. Medicare enrollees should have access to multi-cancer screening tests when the benefit is clinically shown.
Earlier screening for cancer is important because when detected at later stages, treatments are more limited, and outcomes are generally poorer. Medicare enrollees should have access to multi-cancer screening tests when the benefit is clinically shown.
This ACS CAN chartbook provides cancer-specific data related to Medicare, including basic information about the program, a discussion of its components, characteristics of enrollees, coverage of services – specifically those related to prevention and screening – program expenditures and enrollees
The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) along with partners appreciate the opportunity to comment on the Patient Navigation provisions of CY2024 Medicare Physician Fee Schedule.
What does unwinding continuous coverage have to do with Medicaid expansion?
During the pandemic, Congress put in place continuous coverage protections to ensure that Medicaid enrollees were able to keep their health coverage without needing to re-enroll.
What does unwinding continuous coverage have to do with Medicaid expansion?
During the pandemic, Congress put in place continuous coverage protections to ensure that Medicaid enrollees were able to keep their health coverage without needing to re-enroll.
Cancer patients and survivors must balance reducing their health care costs with ensuring they have comprehensive coverage of services, treatments, and care providers.
ACS CAN submitted comments strongly supporting several policy changes that will make it easier to apply for, enroll in, and maintain enrollment in Medicaid and CHIP.
